My research aims to define the effects of a small molecule, metabotropic glutamate receptor (mGluR) Group I agonist 2-chloro-5-hydroxyphenylglycine (CHPG), in a cuprizone-induced model of demyelination in mice. Demyelinating diseases such as Multiple Sclerosis can be very debilitating to patients and most of the current approved therapies treat the immunological component rather than the neurological component of the disease. To this effort, I am investigating the ability of CHPG to increase myelin proteins in addition to the growth factor, brain-derived neurotrophic factor, which has also been shown to play a role in demyelinating diseases.